Mark Wegter is listed as an executive officer and director on 4 SEC Form D filings by 2 issuers between Jun 2019 and Dec 2024: Kiadis Pharma N.V. (Amsterdam, Netherlands (as filed: P7) — biotechnology — 2019; $18.4M reported sold to 25 investors) and EQT Health Economics 3 Cooperatief U.A. (Amsterdam, Netherlands (as filed: P7) — pooled investment fund — 2023–2024; $580K reported sold to 1 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 5 years. Across those companies the filings report $18.9M sold in total.
1 of the issuers belongs to the sponsor group Eqt (248 issuers, $220.24B reported sold, 2012–2026).
What this means A sponsor group is one team that sets up a new company for each deal. Eqt has 248 companies on file and $220.24B reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Mark Wegter and found 3 differences, 1 worth asking the sponsor about: Mark Wegter is no longer listed on the Dec 3, 2025 amendment; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.